

Electronic Acknowledgement Receipt

EFS ID:	5065368
Application Number:	10580709
International Application Number:	
Confirmation Number:	1731
Title of Invention:	Lawsonia Intracellularis 26 Kd Subunit Vaccine
First Named Inventor/Applicant Name:	Paul Vermeij
Customer Number:	31846
Filer:	William Michael Blackstone/Diane Payne
Filer Authorized By:	William Michael Blackstone
Attorney Docket Number:	I-2003.023 US
Receipt Date:	31-MAR-2009
Filing Date:	25-MAY-2006
Time Stamp:	09:50:30
Application Type:	U.S. National Stage under 35 USC 371

Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	\$130
RAM confirmation Number	7128
Deposit Account	022334
Authorized User	

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

Charge any Additional Fees required under 37 C.F.R. 1.492 (National application filing, search, and examination fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.19 (Document supply fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.20 (Post Issuance fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/Message Digest	Multi Part /.zip	Pages (if appl.)
1		Response.pdf	189977 1a1065ed30d9dc2ed74c4595f05e6b7d84d 90f61	yes	8
Multipart Description/PDF files in .zip description					
Document Description		Start		End	
Amendment/Req. Reconsideration-After Non-Final Reject		1		1	
Specification		2		4	
Claims		5		5	
Applicant Arguments/Remarks Made in an Amendment		6		8	

Warnings:

Information:

2	Miscellaneous Incoming Letter	TransmittalLtrSubSeq.pdf	48691 33e2181e06c920a6225decdf2fb72642e009 6a7a	no	3
---	-------------------------------	--------------------------	---	----	---

Warnings:

Information:

3	Sequence Listing (Text File)	SubstituteSequenceListing.txt	6770	no	0
---	------------------------------	-------------------------------	------	----	---

Warnings:

Information:

4	Fee Worksheet (PTO-06)	fee-info.pdf	30364 b563dd877b356f487c0152d602609dab33 9650a4	no	2
---	------------------------	--------------	---	----	---

Warnings:

Information:

Total Files Size (in bytes):	275802
-------------------------------------	--------

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.